Migraine Nervous System Diseases Migraine
Conditions
Interventions
1. Clopidogrel 75 mg orally once daily to be taken for three months
2. Placebo
The study has a one month run-in prior to treatment. After the three month treatment there is no further follow-up.
Sponsors
Guy's and St Thomas NHS Trust (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Age greater than 18 years, either sex 2. Migraine as defined by International Headache Criteria 3. More than two attacks in 28 days
Exclusion criteria
Exclusion criteria: 1. High risk features suggesting cerebral malignancy 2. Contra-indications to clopidogrel 3. Requirements for routine non-steroidal anti-inflammatory agent or aspirin other than for acute headache 4. Use of an investigational product within three months 5. Inability to understand English 6. Pregnancy or breast-feeding 7. Abnormal platelet or liver function
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The number of headache-free days in one month (28 days). Migraine will be assessed using a headache diary kept for 28 days during run-in then again for the final 28 days of the three-month treatment period. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Frequency of attacks 2. Severity of attacks 3. Duration of attacks Migraine will be assessed using a headache diary kept for 28 days during run-in then again for the final 28 days of the three-month treatment period. In addition the patients will have the 6-item Headache Impact Test (HIT-6) and Migraine Disability Assessment (MIDAS) questionnaires at the start and end of the study. | — |
Countries
United Kingdom
Outcome results
None listed